Anti-Infectives: World Markets, 2nd Edition, Vol. I-III (Complete Series)

This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition.
- Antifungals
- Antibacterials
- Antivirals
- Epidemiology including Incidence Statistics for each type of infection.
- Current Market Size and Revenue Forecasts for each market segment to assist with long term planning.
- Discussion of Competitive Products in the market and new products in the delivery pipeline.
- Coverage of Generic Threats for affected major products.
- Round-Up of the Key Players in each area of anti-infectives.
- Over 195 Tables and Figures for easy access to information and decision support tools, internal emails, memos and presentations.
- Discussion of Unique Issues and Emerging Trends for each antibiotic area.
- Market Share of Leading Competitors for each area.
- U.S., Europe, Japan and Rest of World market data.
CHAPTER ONE: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: Introduction
- Overview
- Introduction to Pathogens
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmcokinetics
- Monitoring Therapy
- Combination Therapy and Prophylactic Use
- Fungal Infections
- Types of Fungal Infections
- Superficial
- Systemic
- Histoplasmosis
- Coccidioidomycosis
- Blastomycosis
- Demographics and Statistics
CHAPTER THREE: Systemic Antifungal Drugs
- Overview
- Description of Products
- Allylamines
- Terbinafine (Lamisil - Novartis)
- Azoles
- Fluconazole (Diflucan - Pfizer)
- Ketoconazole (Nizoral, Johnson & Johnson)
- Miconazole (Monistat, Johnson & Johnson)
- Itraconazole (Sporanox, Johnson & Johnson)
- Posaconazole (Noxafil, Schering-Plough)
- Virconazole (Vfend, Pfizer)
- Polyene Macrolides
- Amphotericin B (Ambisome, Astellas; Abelcet, Enzon; Fungizone, Apothecon).
- Griseofluvin (Fulvicin, Schering)
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Flucytosine (Ancoban, Valeant)
- Echinocandins
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FOUR: Topical Antifungal Drugs
- Overview
- Description of Products
- Allylamines
- Naftifine (Naftin, Allergan)
- Terbinafine (Lamisil - Novartis)
- Butenafine (Mentax, Bertek)
- Azoles
- Miconazole (Monistat -Derm, OrthoDermatological)
- Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
- Ketoconazole (Nizoral, J&J; Xolegel, Barrier Therapeutics)
- Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
- Econazole (Spectazole, Ortho Dermatological)
- Sulconazole (Exelderm, Westwood-Squibb)
- Terconazole (Terazol, Ortho Dermatological)
- Polyene Macrolides
- Nystatin (Mycostatin, Westwood Squibb)
- Miscellaneous Antifungals
- Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
- Selenium sulfide (Selsun, Chattem Inc)
- Amorolfine (Loceryl, Roche)
- Alcortin (Iodoquinol, hydrocortisone, Primus Pharmaceuticals)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FIVE: Issues and Trends Affecting the Antifungal Market
- Introduction
- Fungal Infections and Immunocompromised Patients
- Reimbursement
- Infection Imaging
- Expanded Use of Azoles
- Drug Resistance and Interactions
- Standardized Susceptibility Testing
- Generic Impact and Availability
- Importance of Drug Delivery
- Rx-to-OTC Switches
- The Antifungal Market and Enchiocandins
chapter six: Antifungal Drugs: Total Market Size and Forecast
- Overview
- Total market Size and Forecast
CHAPTER SEVEN: Corporate Profiles
- Introduction
- Astellas Pharma Inc
- Barrier Therapeutics, Inc
- Johnson & Johnson Group
- Merck & Company, Inc
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc
- Schering-Plough Corporation
CHAPTER EIGHT: Company Directory
table of exhibits
Chapter One: Executive Summary
- Table 1-1: The World Market for Antifungal Drugs 2004-2011
- Figure 1-1: The World Market for Antifungal Drugs 2004-2011
Chapter Two: Introduction
- Table 2-1: Estimated World and U.S. Incidence of Fungal Infections (thousands)
- Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
- Table 2-2: World Population by Selected Geographical Region, 2006-2050
- Figure 2-2: World Population by Selected Geographical Region, 2006-2050
- Table 2-3: Estimated World Population by Age and Geographical Region, 2006
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2006
- Table 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
- Figure 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
Chapter Three: Systemic Antifungal Drugs
- Table 3-1: Allylamines
- Table 3-2: Azoles
- Table 3-3: Polyene Macrolides
- Table 3-4: Miscellaneous Antifungals
- Table 3-5: New Generic Drug Approvals for Systemic Antifungals, United States, 2004-2006
- Table 3-6: Systemic Antifungal Drugs in Development
- Table 3-7: The Market for Systemic Antifungal Drugs 2004-2011
- Figure 3-1: Systemic Antifungal Drug Market 2004-2011
- Table 3-8: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2004-2010
- Figure 3-2 : Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2004-2010
- Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2004-2011
- Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2006 and 2011
- Table 3-9: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
- Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2006
- Table 3-10: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
- Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2006
- Table 3-11: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
- Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
- Table 3-12: Systemic Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
- Figure 3-8: Systemic Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
- Table 3-13: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
- Figure 3-9: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006
Chapter Four: Topical Antifungal Drugs
- Table 4-1: Allyamines
- Table 4-2: Topical Azoles
- Table 4-3: Polyene Macrolides
- Table 4-4: Miscellaneous Antifungals
- Table 4-5: New Generic Drug Approvals for Topical Antifungals,
- United States, 2004-2006
- Table 4-6: Topical Antifungal Drugs in Development
- Table 4-7: Topical Antifungal Drug Market, 2004-2011
- Figure 4-8: Topical Antifungal Drug Market, 2004-2011
- Table 4-8: Topical Antifungal Drug Market, 2004-2011
- Figure 4-9: Topical Antifungal Drug Market by Product Type - Revenues, 2004-2011
- Figure 4-10: Topical Antifungal Drug Market by Product Type -Percent Distribution, 2004-2011
- Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2006 and 2011
- Table 4-9: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
- Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2006
- Table 4-10 : Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
- Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2006
- Table 4-11: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
- Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
- Table 4-12: Topical Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
- Figure 4-8: Topical Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
- Table 4-13: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
- Figure 4-9: Topical Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006
Chapter Five: Issues and Trends Affecting the
- Antifungal Market
- Table-5-1: New Generic Drug Approvals for Antifungals, United States, 2004-2006
- Table 5-2: Selected Antifungal Rx-to-OTC Switches
Chapter Six: Antifungal Drugs: Total Market
- Size and Forecast
- Table 6-1: The World Market for Antifungal Drugs 2004-2011
- Figure 6-1: The World Market for Antifungal Drugs 2004-2011
- Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2004-2011
- Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2004-2011
- Figure 6-3: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2006 and 2011
Vol II: Antibacterials
Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Introduction The World Market for Anti-Infectives Volume 2:
- Antibacterial Drugs
- Introduction to pathogens
- Classification of Antibacterial Organisms
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-infective Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmacokinetics
- Monitoring Therapy
- Combination Therapy and Prophylactic Use
- Demographics and Statistics
Issues and Trends Affecting the Antibacterial Drug Market
- introduction
- Drug Resistance and Interactions
- Antibiotic Abuse
- Antibiotic Cycling
- addressing market trends
- Antibiotic use in Agriculture
- Antibiotic Education
- Children and Bacterial resistance
- The Elderly and Bacterial Resistance
- Compromised Individuals and Bacterial Resistance
- Screening Hospitalized patients
- Side Effects of Antibiotics
- Partnerships and Alliances
- Environment and Drug Resistance
- Methicillin-resistant Staphylococcus Aureus (MRSA)
Cephalosporin Antibiotics
- Overview
- Description of Products
- First Generation Cephalosporins
- Cephalexin (Keflex, Advancis Pharmaceuticals)
- Cefazolin (Ancef, GlaxoSmithKline; Cefamezin, Astellas)
- Cefadroxil (Duricef, Bristol-Myers Squibb/Warner Chilcot)
- Second Generation Cephalosporins
- Cefuroxime (Ceftin, GlaxoSmithKline)
- Cefoxitin (Mefoxin, Merck)
- Third Generation Cephalosporins
- Cefotaximen (Claforan offered by Sanofi-Aventis)
- Cefoperazone (Cefobid, Pfizer)
- Ceftibutin (Cedax, Shionogi)
- Ceftizoxime (Cefizox, Astellas)
- Ceftriaxone (Rocephin, Roche)
- Ceftazidime (Fortaz, GlaxoSmithKline)
- Cefixime (Suprax, Wyeth/Lupin Pharmaceuticals)
- Cefpodoxime (Vantin, Pfizer)
- Fourth Generation Cephalosporins
- Cefepime (Maxipime, Bristol-Myers Squibb)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Macrolide Antibiotics
- Overview
- Description of Products
- Azithromycin (Zithromax, Pfizer; Zmax, Pfizer)
- Clarithromycin (Biaxin, Abbott Laboratories)
- Erythromycin (Erythrocin, Abbott Laboratories; EryPed, Abbott Laboratories)
- Telithromycin (Ketek, Sanofi-Aventis)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Penicillin Antibiotics
- Overview
- Natural Penicillins
- Penicillinase-Resistant Penicillins
- Broad -Spectrum Penicillins
- Extended-Spectrum Penicillins
Description of Products
- Natural Penicillins
- Penicillin G (Bicillin, King Pharmaceuticals; Pfizerpen, Pfizer)
- Penicillinase-resistant Penicillins
- Cloxacillin (Cloxapen, GlaxoSmithKline)
- Oxacillin (Bactocill, GlaxoSmithKline)
- Broad-spectrum Penicillins
- Amoxicillin (Augmentin, GlaxoSmithKline; Amoxil,GlaxoSmithKline)
- Ampicillin (Unasyn, Pfizer)
- Extended-spectrum Penicillins
- Carbenicillin (Geocillin, Pfizer)
- Piperacillin (Pipracil, Wyeth; Zosyn, Wyeth)
- Ticarcillin (Timentin, GlaxoSmithKline)
Quinolone Antibiotics
- Overview
- Description of Products
- Ciprofloxacin (Cipro, Bayer; Proquin XR, Depomed)
- Gemifloxacin (Factive, LG Chem Ltd. and Oscient Pharmaceuticals)
- Lomefloxacin (Maxaquin, Unimed)
- Nalidixic (NegGram, Sanofi-Aventis)
- Norfloxacin (Noroxin, Merck)
- Ofloxacin (Floxin, Ortho-McNeil)
- Moxifloxicin (Avelox, Bayer; Vigamox, Alcon)
- Levofloxacin (Levaquin, Ortho-McNeil; Tavanic, Sanofi-Aventis; Cravit, Daiichi Sankyo; Quixin, Santen)
- Gatifloxacin (Zymar, Allergan/Kyorin)
- Trovafloxacin (Trovan, Pfizer)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Sulfonamide Antibiotics
- Overview
- Description of Products
- Sulfisoxazole (Gantrisin Pediatric, Roche)
- Oxytetracycline/Sulfamethizole/Phenazopyridine (Urobiotic, Pfizer)
- Erythromycin ethylsuccinate and Sulfisoxazole acetyl (Pediazole, Ross)
- Dapsone (Aczone Gel, QLT USA-Tolmar Inc.)
- Research and Development
- Market Size and Growth
- Competitive Analysis
Tetracycline Antibiotics
- Overview
- Description of Products
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Other Miscellaneous Antibiotics
- Overview
- Description of Products
- Aminoglycosides
- Amikacin Sulfate (Amikin, Bristol-Myers Squibb)
- Kanamycin Sulfate (Kantrex, Bristol-Myers Squibb)
- Neomycin Sulfate (Neo-fradin, X Gen Pharms)
- Streptomycin Sulfate (Streptomycin, Pfizer)
- Lincomycin
- Clindamycin (Cleocin, Pfizer; Clindesse, KV Pharmaceutical Company; Evoclin, Connetics Corp.; Ziana Gel, Medicis/Dow)
- Chloramphenicol
- Chloramphenicol (Chloromycetin,Pfizer)
- Glycopeptide
- Vancomycin (Vancocin, Viropharma)
- Monobactams
- Aztreonam (Azactam, Bristol-Myers Squibb)
- Carbapenems
- Imipenem/cilastatin (Primaxin, Merck)
- Meropenem (Merrem, AstraZeneca)
- Metronidazole
- Metronidazole (Flagyl, Pfizer; Pylera, Axcan; Metrogel-Vaginal, 3M Pharmaceuticals; MetroGel, Galderma)
- Antituberculars
- Rifampicin (Rifater, Sanofi-Aventis)
- Capreomycin (Capastat sulfate, Eli Lilly & Co.)
- Ethionamide (Trecator SC, Wyeth)
- Aminosalicylic acid granules (Paser Granules, Jacobus Pharmaceutical)
- Cycloserine (Seromycin, Eli Lilly & Co.)
- Antileprotics
- Dapsone (Dapsone, Jacobus)
- Oxazolidinones
- Linezolid (Zyvox, Pfizer)
- Ketolides
- Telithromycin (Ketek, Sanofi-Aventis)
- Lipopeptides
- Daptomycin (Cubicin, Cubist Pharmaceutical)
- Glycyclines
- Tigecycline (Tygacil, Wyeth)
- Generic Drug Impact and Availability
- Research and Development
- Market Size and Growth
- Competitive Analysis
Corporate Profiles
- Introduction
- Abbott Laboratories
- AstraZeneca plc
- Bayer Schering Pharma AG
- Cubist Pharmaceuticals, Inc
- Daiichi Sankyo Co., Ltd.
- GlaxoSmithKline
- Johnson & Johnson Group
- King Pharmaceuticals, Inc.
- Merck & Company, Inc.
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Wyeth
Company Names and Addresses
Volume III: Antivirals
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Introduction to Viruses
- Examples of Pathogenic Viruses
- Virus Function and Life History
- Replication in DNA Viruses
- Replication of RNA Viruses
- Replication in Retroviruses
- Host Defenses Against Viruses
- Viral Ploys to Invade Host Cells and Circumvent Host Responses
- Invasion of Host Cells
- Subversion of the Immune Response
- Avoidance of Immune Detection and Attack by Killer Cells
- HIV and AIDS
- Demographics and Epidemiology
- Cytomegalovirus
- Hepatitis B Virus
- Hepatitis C Virus (HCV)
- Herpes
- Human Immunodeficiency Virus (HIV)
- Human Papillomavirus (HPV)
- Influenza
- Respiratory Syncytial Virus (RSV)
- Population Demographics
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors
- Overview
- Description of Products
- Nucleoside Reverse Transcriptase Inhibitors
- Zidovudine (Retrovir, GlaxoSmithKline)
- Didanosine (Videx, Bristol-Myers Squibb)
- Zalcitabine (Hivid, Roche)
- Lamividine(Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
- Stavudine (Zerit, Bristol-Myers Squibb)
- Abacavir (Ziagen, GlaxoSmithKline)
- Nucleotide Analogue Reverse Transcriptase Inhibitors
- Tenofovir (Viread, Gilead Sciences)
- Adefovir dipivoxil (Hepsera, Gilead Sciences)
- Combination Nucleoside Reverse Transcriptase Inhibitors
- Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
- Abacavir and Lamivudine (Kivexa, GlaxoSmithKline)
- Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Nevirapine (Viramune, Boehringer Ingelheim)
- Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
- Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
- Emtricitabine (Emtriva, Gilead Sciences)
- DNA Polymerase Inhibitors
- Acyclovir (Zovirax, GlaxoSmithKline)
- Valacyclovir (Valtrex, GlaxoSmithKline)
- Famciclovir (Famvir, Novartis)
- Penciclovir (Denavir, Novartis)
- Ganciclovir (Cytovene, Roche)
- Ribavirin (Virazole, ICN Pharmaceuticals)
- Foscarnet (Foscavir, AstraZeneca)
- Valganciclovir (Valcyte, Hoffman-LaRoche)
- Cidofovir (Vistide, Gilead Sciences)
- Research and Development
- Baraclude
- Truvada
- Telbivudine
- Viramidine
- Capravirine
- Elvucitabine
- Epzicom
- Etravirine (TMC125)
- GW5634
- MIV 150
- Pradefovir
- Reverset
- TMC278
- Valopicitabine
- Valtorcitabine
- BILR 355
- Calanolide A
- DPC 961 and DPC 963
- GW8248
- MCC-478
- MIV-310
- Market Size and Growth
- Competitive Analysis
Chapter Four: Protease Inhibitors
- Overview
- Description of Products
- Single Agents
- Saquinavir (Fortovase, Hoffman-LaRoche; Invirase, Hoffman-LaRoche)
- Nelfinavir (Viracept, Agouron Pharmaceuticals)
- Indinavir (Crixivan, Merck)
- Ritonavir (Norvir, Abbott Laboratories)
- Amprenavir (Agenerase, GlaxoSmithKline
- Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
- Atazanavir (Reyataz, Bristol-Myers Squibb)
- Combination Protease Inhibitors
- Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
- Research and Development
- Tipranavir (PNU-140690)
- GW640385 (VX-385)
- TMC-114
- BMS232632
- RO033-4649
- VX-950
- Market Size and Growth
- Competitive Analysis
Chapter Five: Other Antivirals
- Overview
- Description of Products
- Aldara
- CytoGam
- Flumadine
- Fuzeon
- Infergen
- Pegasys
- Pegasys + Copegus
- Rebetol, Rebetron
- Relenza
- RespiGam
- Symmetrel
- Synagis
- Tamiflu
- Vistide
- Research and Development
- Attachment and Fusion Inhibitors
- Gene Therapies
- Integrase Inhibitors
- Maturation Inhibitors
- Zinc Finger Inhibitors
- Antisense Drugs
- Cytokines
- Other
- Market Size and Growth
- Competitive Analysis
Chapter Six: Issues and Trends
- Introduction
- Antiviral Drug Resistance
- HIV Drug Cost Controversy
- Antiretroviral Treatment Regimens
- HIV and Women
- Global Surveillance
- Biochemical Prevention and Treatment of Viral Infections
- New Treatment for Hepatitis C
- Costs and Funding of HIV Treatment
- Access to HIV/AIDS Treatment
Chapter Seven: Total Market Size and Forecast
- Overview
- Total Market Size and Forecast
chapter Eight: Corporate Profiles
- Introduction
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline
- MedImmune, Inc.
- Merck & Company, Inc.
- Novartis Pharmaceuticals Corporation
- Roche
- Schering-Plough Corporation
APPENDIX: Company Names and Addresses
List of Exhibits
Chapter One: Executive Summary
- Table 7-1: The World Market for Antiviral Drugs 2002-2009
- Figure 7-1: The World Market for Antiviral Drugs 2002-2009
Chapter Two: Introduction
- Table 2-1: Host Cell Receptors
- Table 2-1: Estimated World and U.S. Incidence of Viral Infections
- Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
- Table 2-2: World Population by Selected Geographical Region, 2004-2050
- Figure 2-2: World Population by Selected Geographical Region, 2003-2050
- Table 2-3: Estimated World Population by Age and Geographical Region, 2004
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2004
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors
- Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors
- Table 3-2: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors
- Table 3-3: Currently Available DNA Polymerase Inhibitors
- Table 3-4: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors in Development (Product, Developer, Phase)
- Table 3-5: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2002-2009
- Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2002-2009
- Table 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2004
- Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2004
- Table 3-7: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2004
- Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2004
- Table 3-8: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2004
- Table 3-9: Estimated Sales and Market Share of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2004
- Figure 3-5: Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2004
Chapter Four: Protease Inhibitors
- Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
- Table 4-2: Protease Inhibitors in Development (Product, Developer, Phase, Earliest Approval Date)
- Table 4-3: The Market for Protease Inhibitors 2002-2009
- Figure 4-1: Protease Inhibitor Market 2002-2009
- Table 4-4: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2004
- Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2004
- Table 4-5: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2004
- Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2004
- Figure 4-4: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2004
Chapter Five: Other Antivirals
- Table 5-1: Currently Available Other Antivirals (Type, Brand, and Manufacturer)
- Table 5-2: Other Antivirals in Development (Product, Developer, Phase, Earliest Approval Date)
- Table 5-3: The Market for Other Antivirals 2002-2009
- Figure 5-1: The Market for Other Antivirals 2002-2009
- Table 5-4: The Market for Other Antivirals Estimated Products Sales by Infection Type, 2004
- Figure 5-2: The Market for Other Antivirals Market Share by Infection Type, 2004
- Table 5-5: The Market for Other Antivirals Estimated Products Sales by Geographic Region, 2004
- Figure 5-3: The Market for Other Antivirals Market Share by Geographic Region, 2004
- Table 5-6: The Market for Other Antivirals Estimated Revenues and Market Share of Leading Suppliers 2004
- Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2004
- Table 5-7: Other Antiviral Market Estimated Sales of Other Antiviral Products 2004
- Figure 5-5: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2004
Chapter Six: Issues and Trends
- Table 6-1: Women (15 to 49) Living with HIV/AIDS by Region 2004
- Table 6-2: Funding for HIV/AIDS
- Table 6-3: Access Needs of Adults and Children with HIV by Region 2004
- Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region in the Developing World
Chapter Seven: Total Market Size and Forecast
- Table 7-1: The World Market for Antiviral Drugs 2002-2009
- Figure 7-1: The World Market for Antiviral Drugs 2002-2009
- Table 7-2: World Market for Antiviral Drugs by Type 2002-2009
- Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2002-2009